Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a progressive clinical-stage biotechnology company committed to developing transformative therapies targeting neurodegenerative and lung diseases. The company leverages innovative drug-delivery technologies to create novel treatments aimed at improving patient outcomes.
Key to Tiziana's portfolio are two prominent compounds: Milciclib and Foralumab. Milciclib, an inhibitor of cyclin-dependent kinases, is in Phase II clinical trials for thymic carcinoma, aiming to provide new hope for patients who have exhausted chemotherapy options. Foralumab, noted for being the only fully human-engineered anti-CD3 monoclonal antibody, is in various stages of clinical development for multiple sclerosis, autoimmune, and inflammatory diseases.
In a significant advancement, Tiziana recently reported positive clinical outcomes from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS). Intranasal administration of Foralumab led to remarkable improvement in fatigue symptoms in 70% of patients over six months, as measured by the Modified Fatigue Impact Scale (MFIS). These results signify a groundbreaking step in addressing an unmet need in MS treatment.
The company's commitment to innovation is backed by strategic partnerships with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital. Tiziana’s leadership team brings extensive experience in drug development and commercialization, ensuring a firm trajectory toward regulatory approvals and market entry.
Moreover, Tiziana’s pipeline includes potential therapies for conditions like ALS, Alzheimer's, and Crohn's Disease, underscoring its dedication to tackling a broad spectrum of debilitating conditions. The company’s forward-looking approach aims to revolutionize treatment paradigms through enhanced drug delivery systems that promise increased efficacy and reduced side effects.
With a robust clinical pipeline, strategic collaborations, and innovative technologies, Tiziana Life Sciences Ltd. remains at the forefront of biopharmaceutical research, poised to make significant strides in the field of immunomodulation therapies.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has filed a Form 20-F with the SEC to finalize the distribution of shares in Accustem Sciences Limited to its shareholders in the US through the ADS program. This move will separate Accustem as an independent entity, allowing it to pursue its own listing. Shareholders can access detailed information about Accustem via the SEC report linked in the press release.
Tiziana Life Sciences (NASDAQ: TLSA) announced plans for a phase 2 clinical trial of Foralumab, a nasally administered anti-CD3 monoclonal antibody targeting Covid-19. Previous studies indicated Foralumab reduced lung inflammation in mild to moderate cases. The new trial will focus on hospitalized patients in Brazil and aims to validate Foralumab's effectiveness and safety as a nasal immunomodulatory therapy. This innovative approach leverages Foralumab's unique nasal delivery system to potentially alleviate severe Covid-19 symptoms, irrespective of viral variants.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has announced that its Chairman, Gabriele Cerrone, will appear on Bloomberg Television on March 30, 2021, at 1:50 PM US Eastern Time. This update corrects the previously announced schedule. Tiziana focuses on developing innovative therapies for oncology and inflammation, including Milciclib and Foralumab, the latter being a fully human anti-CD3 monoclonal antibody for various autoimmune and inflammatory diseases. The company is also advancing an anti-IL6R monoclonal antibody for treating COVID-19 related inflammation.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announces that Chairman Gabriele Cerrone will appear on Bloomberg Television on March 29, 2021, at 1:20 PM EST. This interview will be featured on the Bloomberg Surveillance Show. Tiziana Life Sciences is a UK biotechnology firm concentrating on therapeutics for oncology and immunology, with ongoing developments such as Milciclib and Foralumab, which is a fully human anti-CD3 monoclonal antibody. The company is also advancing an anti-IL6R monoclonal antibody aimed at treating COVID-19 patients.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announced that CEO Dr. Kunwar Shailubhai will appear on The RedChip Money Report airing on Bloomberg Television. The interview is set for February 27, 2021, at 7 p.m. EST in the U.S., and February 28, 2021, at 6 p.m. CET in Europe. Dr. Shailubhai will discuss topline data from the COVID-19 trial and upcoming Phase 2 trials for innovative therapeutics, including Foralumab, targeting various autoimmune diseases.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced its participation in the BIO CEO & Investor Digital Conference from February 16-18, 2021. CEO Dr. Kunwar Shailubhai emphasized the company's focus on innovative therapeutics, highlighting topline data from a recent COVID-19 trial and upcoming Phase 2 trials in 2021. Tiziana is advancing its monoclonal antibody Foralumab for multiple autoimmune diseases and is accelerating the development of an anti-IL6 receptor antibody, important for treating inflammation related to various conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has appointed Dr. Thomas Adams as the new executive director and Head of Drug Development. With a Ph.D. in Biochemistry, Dr. Adams brings extensive experience from roles at Cardiff Oncology and Hepion Pharmaceuticals. His leadership is expected to enhance the development of Tiziana's oncology programs, including Milciclib and Foralumab, which target various cancers and inflammatory diseases. The Company aims to leverage his background in precision medicine to accelerate therapeutic advancements. Notably, Dr. Adams previously faced involvement in Synergy Pharmaceuticals, which filed for bankruptcy in 2018.
Tiziana Life Sciences (NASDAQ:TLSA) announced an interview with CEO Dr. Kunwar Shailubhai discussing the therapeutic potential of Foralumab for COVID-19. The nasal administration of Foralumab demonstrated nearly double the improvement in lung CT scans compared to a control group. This proprietary nasal delivery aims to modulate immunity and alleviate symptoms, especially with emerging COVID-19 variants in the UK, South Africa, and Brazil. Tiziana is also developing Foralumab for liver diseases and has ongoing projects targeting various autoimmune conditions.
On January 27, 2021, Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of a "universal" shelf registration statement with the SEC for up to $250 million in securities. This move allows for efficient access to U.S. capital markets. The registration includes a preliminary prospectus for an "at-the-market" sales agreement with B. Riley Securities, enabling the potential sale of up to $100 million in American Depositary Shares. Notably, Tiziana has no immediate plans for any offerings under this registration.
Tiziana Life Sciences announced that its CEO and CSO, Dr. Kunwar Shailubhai, will host a fireside chat on January 21, 2021, at 3 PM ET / 8 PM GMT. The discussion will provide updates on the company's ongoing developments, particularly in oncology and inflammation. Tiziana is advancing therapeutics such as Foralumab, a fully human anti-CD3 monoclonal antibody, and its IL6R monoclonal antibody for treating COVID-19. Interested parties can join the webcast through a provided link.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
What is Tiziana Life Sciences Ltd. specialized in?
What are the key compounds in Tiziana's pipeline?
What recent clinical results has Tiziana announced?
Who are Tiziana Life Sciences' key partners?
What diseases are targeted by Foralumab?
What is unique about Tiziana’s drug delivery approach?
What is the status of Milciclib's clinical development?
Who leads Tiziana Life Sciences?
What is the significance of Tiziana's Expanded Access Program?
How does Tiziana Life Sciences contribute to biopharmaceutical research?
